The role of factor Xa inhibitors in venous thromboembolism treatment

Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabral, Katherine P, Ansell, Jack E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321604/
https://www.ncbi.nlm.nih.gov/pubmed/25673997
http://dx.doi.org/10.2147/VHRM.S39726
_version_ 1782356286322507776
author Cabral, Katherine P
Ansell, Jack E
author_facet Cabral, Katherine P
Ansell, Jack E
author_sort Cabral, Katherine P
collection PubMed
description Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.
format Online
Article
Text
id pubmed-4321604
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43216042015-02-11 The role of factor Xa inhibitors in venous thromboembolism treatment Cabral, Katherine P Ansell, Jack E Vasc Health Risk Manag Review Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice. Dove Medical Press 2015-01-30 /pmc/articles/PMC4321604/ /pubmed/25673997 http://dx.doi.org/10.2147/VHRM.S39726 Text en © 2015 Cabral and Ansell. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Cabral, Katherine P
Ansell, Jack E
The role of factor Xa inhibitors in venous thromboembolism treatment
title The role of factor Xa inhibitors in venous thromboembolism treatment
title_full The role of factor Xa inhibitors in venous thromboembolism treatment
title_fullStr The role of factor Xa inhibitors in venous thromboembolism treatment
title_full_unstemmed The role of factor Xa inhibitors in venous thromboembolism treatment
title_short The role of factor Xa inhibitors in venous thromboembolism treatment
title_sort role of factor xa inhibitors in venous thromboembolism treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321604/
https://www.ncbi.nlm.nih.gov/pubmed/25673997
http://dx.doi.org/10.2147/VHRM.S39726
work_keys_str_mv AT cabralkatherinep theroleoffactorxainhibitorsinvenousthromboembolismtreatment
AT anselljacke theroleoffactorxainhibitorsinvenousthromboembolismtreatment
AT cabralkatherinep roleoffactorxainhibitorsinvenousthromboembolismtreatment
AT anselljacke roleoffactorxainhibitorsinvenousthromboembolismtreatment

Ejemplares similares